Skip to main content
. Author manuscript; available in PMC: 2023 Oct 25.
Published in final edited form as: Cell Rep. 2023 Sep 13;42(9):113132. doi: 10.1016/j.celrep.2023.113132

Figure 1. Principal characteristics of MP41 and MP46 PDXs established from aggressive uveal melanomas.

Figure 1.

(A) Clinical characteristics of UM cases.

(B) Main molecular characteristics of corresponding patient-derived xenograft models established and characterized previously.21 Mutational status was assessed with Sanger sequencing (GNAQ/GNA11, BAP1, SF3B1, EIF1AX), with Cytoscan HD microarrays for copy number analysis and BAP1 immunohistochemistry from formalin-fixed paraffin-embedded (FFPE) tissue section.